Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy.
Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara, Türkiye.
Anticancer Drugs. 2024 Oct 1;35(9):878-881. doi: 10.1097/CAD.0000000000001638. Epub 2024 Jul 23.
Rituximab is an anti-CD20 chimeric murine/human mAb mainly used to treat certain types of lymphoproliferative malignancies and autoimmune diseases. Although it has been used in the treatment of vasculitis in recent years, it rarely triggers severe vascular skin reactions such as leukocytoclastic vasculitis (LCV). Physicians should be aware of this rare adverse event that requires discontinuation of rituximab, which can occur days or even weeks after rituximab treatment. Here, we report a case of LCV observed in a patient with low-grade orbital B-cell lymphoma treated with weekly rituximab and local radiotherapy. In our case, discontinuation of rituximab and initiation of oral methylprednisolone therapy were sufficient to achieve complete resolution of the LCV.
利妥昔单抗是一种抗 CD20 的嵌合鼠/人单克隆抗体，主要用于治疗某些类型的淋巴增生性恶性肿瘤和自身免疫性疾病。虽然近年来已用于血管炎的治疗，但很少引发白细胞碎裂性血管炎（LCV）等严重的血管皮肤反应。医生应意识到这一罕见的不良事件，需要停用利妥昔单抗，这种情况可在利妥昔单抗治疗后数天甚至数周发生。在此，我们报告了一例接受每周利妥昔单抗和局部放疗治疗的低级别眼眶 B 细胞淋巴瘤患者发生 LCV 的病例。在我们的病例中，停用利妥昔单抗并开始口服甲基强的松龙治疗足以完全缓解 LCV。
